Anti-clotting drug rivaroxaban wins FDA panel's support

03/19/2009 | NYTimes.com

A panel of FDA advisers endorsed the approval of rivaroxaban, an anti-coagulant by Johnson & Johnson and Bayer Healthcare Pharmaceuticals, as a preventive treatment for deep-vein thrombosis and pulmonary embolism in patients undergoing total knee- or hip-replacement surgery. The product could become an alternative to blockbuster drug warfarin if it gains final FDA clearance.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC